Drug Profile
Research programme: lung disorder therapeutics - Aileron Therapeutics/University of Texas Health Sciences Center at Tyler
Alternative Names: LTI-02; scuPA; Single chain urokinase plasminogen activatorLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator Lung Therapeutics; University of Texas at Tyler
- Developer Aileron Therapeutics; University of Texas at Tyler
- Class Amino acids; Antifibrotics; Peptides; Plasminogen activator enzymes
- Mechanism of Action Fibrinolytic agents; Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury
Most Recent Events
- 31 Oct 2023 Lung Therapeutics has been acquired and merged into Aileron Therapeutics
- 28 Nov 2018 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Inhalation)
- 28 Oct 2014 Preclinical trials in Acute lung injury in USA (Inhalation)